Beuers U, Oswald M
Medizinische Klinik II, Klinikum Grosshadern der LMU München.
Ther Umsch. 1998 Feb;55(2):97-103.
Ursodeoxycholic acid (UDCA) has been shown to be both an effective and well-tolerated treatment of primary biliary cirrhosis, a model chronic cholestatic liver disease. Beneficial effects of UDCA have also been observed in other cholestatic disorders such as primary sclerosing cholangitis, cystic fibrosis, or intrahepatic cholestasis of pregnancy. Liver transplantation is the treatment of choice in end stage chronic cholestatic liver disease. Symptomatic therapeutic concepts include the treatment of cholestasis-associated problems such as pruritus, osteopathy and vitamin deficiency.
熊去氧胆酸（UDCA）已被证明是治疗原发性胆汁性肝硬化（一种典型的慢性胆汁淤积性肝病）的有效且耐受性良好的药物。在其他胆汁淤积性疾病如原发性硬化性胆管炎、囊性纤维化或妊娠期肝内胆汁淤积症中也观察到了UDCA的有益作用。肝移植是终末期慢性胆汁淤积性肝病的首选治疗方法。对症治疗方案包括处理与胆汁淤积相关的问题，如瘙痒、骨病和维生素缺乏。
